Antibiotic-Resistant STIs: Men's Health Is Entering A New Era Of Therapeutic Risk

By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals

For decades, sexually transmitted infections (STIs), such as gonorrhea and chlamydia, were viewed as straightforward to treat. A single injection or short oral course of antibiotics was typically sufficient. That era is rapidly changing.

Antimicrobial resistance (AMR) is reshaping the clinical landscape of bacterial STIs, particularly Neisseria gonorrhoeae. What was once a reliably treatable infection is increasingly defined by resistance patterns that limit therapeutic options and complicate management, especially in men’s reproductive and sexual health.^1,2

The scale of the problem is substantial. The World Health Organization estimated roughly 374 million new cases of four curable STIs in 2020, with chlamydia and gonorrhea making up much of that burden.¹ But the margin of safety is already narrowing. AMR is spreading, studies attribute more than a million deaths each year to drug‑resistant infections,¹ and economists warn that unchecked antimicrobial resistance could impose up to $1 trillion in additional healthcare costs by 2050 and $1 trillion to 3.4 trillion in annual global GDP losses by 2030, according to World Bank estimates.² In practical terms, that means common infections that were once reliably cured are increasingly harder and more expensive to treat, driving worse outcomes — from infertility to neonatal loss — and placing growing strain on already fragile health services.¹

The Growing Clinical Complexity Of Gonorrhea

Neisseria gonorrhoeae has demonstrated a remarkable capacity to develop resistance to multiple antibiotic classes over time. Historically, resistance has emerged against the sulfonamides, tetracyclines, macrolides, and fluoroquinolones antibiotic classes.³ Reduced susceptibility to extended-spectrum cephalosporins, including ceftriaxone, also has been reported.⁴

The clinical fallout should not be underestimated. Treatment failures leave infections unchecked long enough to invade tissues, producing pelvic inflammatory disease, abscesses, and scarring.⁵ In some patients, the bacteria disseminate, causing septic arthritis, endocarditis, or meningitis.⁶ In newborns, untreated maternal infection can lead to ophthalmia neonatorum and permanent blindness.⁷ As oral options fail, clinicians must resort to more toxic hospital‑based regimens or limited‑availability drug combinations, which can still fail and allow infections to progress to a systemic, life‑threatening disease.³

In the United States, ceftriaxone remains the recommended first-line treatment for uncomplicated gonorrhea.⁸ However, reliance on a single injectable option presents clinical and public health challenges, particularly if resistance trends continue.

Compounding this issue is the high frequency of co-infection with Chlamydia trachomatis.⁸ Current treatment paradigms often require separate agents to address both gonorrhea and chlamydia, which are frequently co-reported and remain among the most common bacterial sexually transmitted infections, with recommended regimens using ceftriaxone for gonorrhea and doxycycline for chlamydia.^1,9 This highlights a critical unmet need for oral treatment strategies that can effectively address common co-infection scenarios.

Resistance Mechanisms: More Than Target Mutations

Antibiotic resistance in N. gonorrhoeae is not driven solely by mutations in drug targets. The organism also employs efflux pumps, permeability changes, and horizontal gene transfer to reduce intracellular antibiotic exposure and accelerate resistance acquisition.¹⁰

These layered resistance mechanisms limit the durability of incremental modifications to existing drug classes. Historically, many development efforts have focused on refining known antibiotic scaffolds, only to encounter rapid resistance emergence.¹⁰ As a result, there is growing recognition that fundamentally different mechanistic approaches may be necessary to restore treatment flexibility in resistant STIs.¹⁰

Rethinking Antimicrobial Strategy

Rather than relying exclusively on stronger derivatives of existing antibiotics, some research efforts are now focused on targeting bacterial processes that remain essential across resistant strains.

One area of renewed interest involves next-generation dihydrofolate reductase (DHFR) inhibitors. DHFR is a critical enzyme in bacterial folate metabolism and nucleotide synthesis.¹¹ By selectively inhibiting this pathway, investigators aim to disrupt bacterial growth through mechanisms distinct from fluoroquinolones, macrolides, or beta-lactams.¹¹

Importantly, modern DHFR-focused research differs from earlier trimethoprim-based approaches by incorporating structural modifications designed to overcome known resistance mutations and enhance activity against intracellular pathogens.¹¹

The intracellular nature of Chlamydia trachomatis presents an additional challenge, as compounds must achieve effective concentrations within host cells. Mechanism-driven antimicrobial discovery increasingly considers both resistance genetics and intracellular pharmacodynamics as part of drug design.¹¹

A Men’s Health Imperative

Discussions of men’s health often focus on cardiovascular disease, cancer, and mental well-being. Antibiotic resistant STIs rarely receive similar attention, despite their direct impact on reproductive health, sexual health, and quality of life.

Untreated or difficult-to-treat gonorrhea can result in epididymitis, prostatitis, and potential infertility.⁵ As treatment options narrow, early detection, prevention, and sustained innovation in antimicrobial research become even more critical.³

Addressing antibiotic-resistant STIs will require more than surveillance and stewardship alone. It will require investment in novel mechanisms, durable therapeutic strategies, and research approaches that anticipate — rather than react to — bacterial evolution.¹

The therapeutic landscape for bacterial STIs is not yet at a crisis point. But the trajectory is clear. Without continued innovation in antimicrobial development, infections that were once routine to treat could become significantly more complex.

The next era of men’s health may depend on how effectively the scientific community responds today.

References

1. Centers For Disease Control & Prevention. Sexually Transmitted Infections Surveillance, 2024 (Provisional), September, 2025. Center For Disease Control. https://www.cdc.gov/sti-statistics/annual/index.html
2. World Health Organization. Antimicrobial Resistance. 21 Nov. 2023, https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
3. National Library of Medicine. The frequency of co-infection with Neisseria gonorrhoeae and Chlamydia trachomatis in men and women in eastern Sydney. June, 2010. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/8714280/.
4. Whiley, David M., et al. “Reduced Susceptibility to Ceftriaxone in Neisseria gonorrhoeae Is Spread Internationally by Genetically Distinct Gonococcal Populations.” Journal of Antimicrobial Chemotherapy, vol. 66, no. 5, May 2011, pp. 1186–1187. Oxford University Press, https://doi.org/10.1093/jac/dkr052.
5. World Health Organization. Gonorrhoea (Neisseria gonorrhoeae Infection). World Health Organization, https:/www.who.int/news-room/fact-sheets/detail/gonorrhoea-(neisseria-gonorrhoeae-infection).
6. California Department of Public Health. Disseminated Gonococcal Infection (DGI). https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Disseminated-Gonococcal-Infection.aspx.
7. Centers for Disease Control and Prevention. Gonococcal Infections Among Neonates. CDC, https://www.cdc.gov/std/treatment-guidelines/gonorrhea-neonates.htm.
8. Mayo Clinic. Ceftriaxone (injection route), January, 2026. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/ceftriaxone-injection-route/description/drg-20073123
9. Workowski, Kimberly A., et al. “Sexually Transmitted Infections Treatment Guidelines, 2021.” Clinical Infectious Diseases, vol. 74, suppl. 2, 2022, pp. S95–S104. https://doi.org/10.1093/cid/ciab1018.
10. National Library of Medicine. Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy, 2023. National Library of Medicine https://pmc.ncbi.nlm.nih.gov/articles/PMC10744250/#:~:text=The%20growing%20threat%20
    of%20antibiotic,and%20Development%20of%20New%20Antibiotics%E2%80%9D.
11. National Library of Medicine. Chemical Space of Escherichia coli Dihydrofolate Reductase Inhibitors: New Approaches for Discovering Novel Drugs for Old Bugs. September, 2018. National Library of Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC6370515/

About The Author

Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals, has more than 20 years of experience in the life sciences industry as a sales, marketing, business development, and licensing and acquisition professional. He remains partner at MFP, LP, a private equity investment entity focused on the life sciences sector. Mario is also a director at Evogen, Inc., a development stage laboratory diagnostics company focused on central nervous system disease management.